Images List Premium Download Classic

Autoimmune

Autoimmune-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases
Universita' Degli Studi Di Roma "la Sapienza"
September 14, 2017 - N°20170261505

The present invention relates to the use of one or more mhc class i molecules dextramers (dextramers®) associated with peptides corresponding to apoptotic epitopes of human cd8+ t cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit tnf, and/or ...
Oral administration of an anti-cd20 antibody for treatment of autoimmune disease
Universita' Degli Studi Di Roma "la Sapienza"
September 14, 2017 - N°20170260283

The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-cd20 antibody is administered to the subject. Oral administration of such antibodies as rituximab, ocrelizumab, ofatumumab, obinutuzumab, tositumomab, or ibritumomab are useful in a method of decreasing innate inflammatory cytokines, such as and tnf-a, ...
Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the ...
The General Hospital Corporation
September 14, 2017 - N°20170260245

The invention features homo-multimers, e. G., homo-trimers, of tnfsf or tnf-like ligand muteins in which each tnfsf ligand or tnf-like ligand mutein monomer contains at least one cysteine residue substitution or insertion that promotes the formation of a disulfide bond with a cysteine residue on a neighboring tnfsf or tnf-like ligand mutein monomer. The invention features methods of producing such ...
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Phosphonate compounds for treatment of complement mediated disorders
Achillion Pharmaceuticals, Inc.
September 14, 2017 - N°20170260219

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is a phosphonate (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the ...
Dihydropyrrolopyridine inhibitors of ror-gamma
Achillion Pharmaceuticals, Inc.
September 14, 2017 - N°20170260180

Pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by rorγ. Also provided are pharmaceutical compositions comprising the novel compounds of formula (i) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
Indole carboxamide compounds
Achillion Pharmaceuticals, Inc.
September 14, 2017 - N°20170260160

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic ...
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for modified t cells
The Trustees Of The University Of Pennsylvania
September 14, 2017 - N°20170258835

The present invention relates to compositions and methods for generating modified cells with nucleic acid encoding a t cell receptor (tcr), a nucleic acid encoding a bispecific antibody, affinity molecule chimeric receptor, bispecific affinity molecule, or a chimeric ligand engineered activation receptor (clear). One aspect includes a method for generating a modified t cell. Also included are methods and pharmaceutical ...
Fgl2 expressing regulatory t cells
Veritas Therapeutics Inc.
September 14, 2017 - N°20170258834

This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory t cells (treg) and associated compositions for the induction of immune tolerance are described. The methods and uses may be used to prevent transplant rejection, and in the treatment of diseases or conditions such as graft versus host disease, autoimmune disease and allergies. ...
Therapeutic detoxification compositions and methods of making and using same
Immutrix Therapeutics, Inc.
September 14, 2017 - N°20170258832

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.
Treatments for autoimmune disease
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board,of The College Of The Holy
September 14, 2017 - N°20170258797

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for ...
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Pharmacyclics Llc
September 14, 2017 - N°20170258729

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, ...
Method for the detection of antigen presentation
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts
September 07, 2017 - N°20170254803

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. The binding agents of the invention are coupled to proximity probes which ...
Low dose immune checkpoint blockade in metastatic cancer
Lodoco Clinical Kft.
September 07, 2017 - N°20170253655

A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-ctla-4 antibodies. The invention provides methods for low dose immune checkpoint (ic) treatment of metastatic cancer by delivering anti-ctla-4 and anti-pd-1 antibodies to cancer patients. Methods also provide for il-2 stimulation for the activation of t cells against tumor cells. The invention further provides methods for ...
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
Incyte Holdings Corporation
September 07, 2017 - N°20170253598

The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jaks) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Liquid formulation comprising gm-csf neutralizing compound
Takeda Gmbh
September 07, 2017 - N°20170252436

The present invention relates to aqueous formulations comprising a compound neutralizing gm-csf in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing gm-csf in view of long-term storage. In ...
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases
Chr. Hansen A/s
September 07, 2017 - N°20170252369

The embodiments herein relate to a therapeutic method for the treatment of parkinson disease, other neurodegerative disorders, and autoimmune diseases. The method includes providing sodium thiosulfate through any method of administration (orally, intravenously, through inhalation, intravesically, vaginally, rectal route, sublingually, ophthalmically, or topically) and is given with one or more pharmaceutically acceptable carriers or excipients. The sodium thiosulfate safely and ...
Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry ...
The Board Of Trustees Of The University Of Arkansas Acting For And On Behalf Of The Universit
September 07, 2017 - N°20170252347

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (sma) syndrome (sma1, sma2, sma3, and sma4, also called type i, ii, iii and iv), traumatic brain injury (tbi), concussion, keratoconjunctivitis sicca (dry eye disease), glaucoma, sjogren's syndrome, rheumatoid arthritis, post-lasik surgery, anti-depressants use, wolfram ...
Nucleic acid capable of inhibiting expression of beta-2gpi
Kyowa Hakko Kirin Co., Ltd.
August 31, 2017 - N°20170247701

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.
Nucleic acid capable of inhibiting expression of beta-2gpi
Kyowa Hakko Kirin Co., Ltd.
August 31, 2017 - N°20170247700

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.
Modulation of ptpra to treat arthritis
The Regents Of The University Of California
August 31, 2017 - N°20170247469

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (pt-pra) antagonist.
Loading